European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables by Launonen, V et al.
Loss of heterozygosity (LOH) for a specific chromosome region
may indicate the presence of a tumour suppressor gene (TSG).
Studies on tumour LOH have therefore been helpful to identify
many TSGs (Bièche and Lidereau, 1995). High incidences of LOH
of the 11q22-qter chromosome region have been seen in breast
cancer (Hampton et al, 1994; Gudmundsson et al, 1995; Negrini et
al, 1995; Winqvist et al, 1995; Kerangueven et al, 1997; Laake et al,
1997) and also in several other human malignancies (Herbst et al,
1995; Rasio et al, 1995; Gabra et al, 1996; Hui et al, 1996). In addi-
tion, it has been shown that chromosome 11 can suppress tumori-
genicity when transferred to breast cancer (Negrini et al, 1994;
Phillips et al, 1996) and melanoma cell lines (Robertson et al, 1996).
The distal half of chromosome 11q contains several genes
indicated to be involved in tumorigenesis; e.g. ATM (the ataxia
telangiectasia disorder gene at 11q23.1), DDX10 (a putative RNA
helicase gene at 11q23.1), MLL1 (a gene at 11q23 frequently
rearranged in acute leukaemia), LOH11CR2A (a potential tumour
suppressor gene at 11q23) and CHEK1 (a gene at 11q24 encoding
a protein kinase required for the DNA damage checkpoint func-
tion) (Ziemin-van der Poel et al, 1991; Savitsky et al, 1995, 1996;
Furnari et al, 1997; Monaco et al, 1997; Sanchez et al, 1997).
LOH at 11q23 has been reported in association with poor post-
metastatic survival in breast cancer (Winqvist et al, 1995). The
crucial region of LOH seemed to map between loci D11S35
(11q22) and APOC3 (apolipoprotein C-3 at 11q23) (Hampton et
al, 1994), in a chromosomal segment of less than 17 Mb (Arai et
al, 1996). In the initial study of a Finnish breast cancer cohort,
APOC3 appeared to be the most suitable marker for more careful
examinations of the clinical effects of LOH of the 11q23 chromo-
somal region. Therefore, in the present European multicen-
trestudy, we analysed tumour and normal tissue pairs of 766
primary breast cancer patients from 11 countries to investigate the
association between LOH at the APOC3 locus and clinical vari-
ables in greater detail.
MATERIALS AND METHODS
Altogether 766 primary tumour and normal tissue pairs from
breast cancer patients were collected for the LOH analysis. The
European multicenter study on LOH of APOC3 at 11q23
in 766 breast cancer patients: relation to clinical
variables
V Launonen1, K Laake4, P Huusko1, D Niederacher5, MW Beckmann5, RB Barkardottir6, EK Geirsdottir6,
J Gudmundsson6, P Rio7, Y-J Bignon8, S Seitz9, S Scherneck9, I Bièche10, M-H Champème10, D Birnbaum11,
G White12, J Varley12, M Sztán13, E Olah13, A Osorio14, J Benitez14, N Spurr15*, N Velikonja16, B Peterlin16, Å Borg17,
A-M Cleton-Jansen18, P Devilee18, R Bloigu2, R Lidereau10, A-L Børresen-Dale4, R Winqvist1,3, and the Breast Cancer
Somatic Genetics Consortium
Departments of 1Clinical Genetics, 2Mathematical Science/Statistics and 3Oncology and Radiotherapy, University of Oulu/Oulu University Hospital, Oulu,
Finland; 4Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway; 5Department of Obstetrics and Gynecology,
Heinrich-Heine-University, Düsseldorf, Germany; 6Laboratory of Cell Biology, Department of Pathology, University Hospital of Iceland, Reykjavik, Iceland;
7INSERM U 484 Clermont-Ferrand, France; 8Laboratoire d’Oncologie Moléculaire INSERM CRI 9502 and EA 2145, Centre Jean Perrin, Clermont-Ferrand,
France; 9Department of Tumour Genetics, Max-Delbrück-Centrum, Berlin, Germany; 10Centre René Huguenin, Saint-Clod, France; 11Institut Paoli-Calmettes and
U.119 INSERM, Marseille, France; 12Section of Molecular Genetics, Paterson Institute for Cancer Research, Manchester, UK; 13National Institute of Oncology,
Budapest, Hungary; 14Department of Genetics, Fundación Jiménez Díaz, Madrid, Spain; 15Human Genetic Resources, ICRF, Clare Hall, Laboratories, London,
UK; 16Division of Medical Genetics, Department of Obstetrics and Gynaecology, Ljubjana, Slovenia; 17Institute of Oncology, University Hospital, Lund, Sweden;
18Department of Pathology, Leiden University, Leiden, The Netherlands
Summary High frequencies of loss of heterozygosity (LOH) in chromosome 11q22-qter have been observed in various malignancies,
including breast cancer. Previous studies on breast carcinomas by Winqvist et al (Cancer Res 55: 2660–2664) have indicated that a survival
factor gene is located in band 11q23, and that the highly informative microsatellite polymorphism at the APOC3 locus would be a suitable tool
to perform more extensive LOH studies. In this European multicentre study, we have examined the occurrence of APOC3 LOH and evaluated
the effect of LOH of this chromosomal subregion on the clinical behaviour of the disease in a cohort of 766 breast cancer patients in more
detail. LOH for APOC3 was found in 42% of the studied tumours, but it was not found to be significantly associated with any of the studied
clinical variables, including cancer-specific survival time or survival time after recurrent/metastatic disease. According to the present findings,
the putative survival factor gene on 11q23 is not located close enough to the APOC3 gene, but apparently at a more proximal location.
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studied patient material was collected from 15 different research
centres, representing 11 European countries (Table 1). Clinical
characteristics are summarized in Tables 1 and 2. The patients
studied were diagnosed with primary breast cancer between 1978
and 1996. The mean age of disease onset was 57 years (range
27–95). The mean follow-up time of those patients still alive was
57 months (range 1–198). Information about the family history of
breast/ovarian cancer (in two or three first-degree relatives) and
disease bilaterality was also collected. Tumours were classified
according to size (< 2 cm, 2–5 cm or > 5 cm in diameter),
histology, histoprognostic grade, and oestrogen receptor and pro-
gesterone receptor status. In addition, information about node and
metastasis status at the time of diagnosis and possible adjuvant
cancer therapy was obtained. Twenty-eight (4.7%) of the patients
presented with metastatic disease at the time of diagnosis, while an
additional 203 patients displayed local and/or distal tumour
recurrence/metastasis during the clinical follow-up time. All cases
from Sweden and the Netherlands were selected according to a
metastatic disease course during the clinical follow-up time.
DNA from tumour tissue (fresh or paraffin-embedded) and
corresponding normal tissue (blood, fresh or paraffin-embedded
tissue) was extracted using standard phenol–chloroform protocols.
Only a minority of the tissue material used was from paraffin-
embedded tissues (2%, (17/766), all cases from Slovenia). In these
cases DNA was extracted using the methods described by Sarkar
(1995). The LOH analysis using the highly informative mono-
nucleotide repeat microsatellite marker APOC3 (Bhattacharya
et al, 1991) was performed either in Oulu or in the research centre
from where the tissue material was collected. Polymerase chain
reaction (PCR) was performed mainly as described previously
(Bhattacharya et al, 1991), with some slight modifications, e.g.
alternatively using radioactive or non-radioactive PCR methods.
In the radioactive protocols we used either direct incorporation of
[a-32]-dCTP or [32P]-end-labelled PCR primers. Two different
non-radioactive PCR protocols were used. One utilized silver
staining to visualize the PCR products after electrophoresis. The
other method used fluorescent-labelled PCR primers and an auto-
mated DNA sequencer for fragment analysis (Pharmacia, ALF;
Perkin-Elmer Applied Biosystems, model 373A). In all cases,
the PCR products were resolved by electrophoresis on 6–7%
denaturing polyacrylamide gels. The evaluation of LOH status
was performed in the radioactive method by comparing the normal
and tumour tissue allele intensity ratios of the autoradiograms.
Each case was evaluated by at least two independent viewers who
Table 1 Clinical characteristics of the studied European breast cancer cohort
Country Number of Period of collection Mean age of Mean follow-up Positive family Bilateral Recurrent/metastatic
patients disease onset time in months history disease disease course
(range) (range) (cases) (cases) (cases)
Finland 85 1988–90 57 (29–84) 75 (5–117) 7 5 39
France I 46 1993–95 60 (35–87) – – 2 –
France II 48 1978–87 53 (27–86) 123 (11–198) – 0 25
France III 61 1988–96 61 (31–84) 32 (3–104) 31 5 5
Germany I 52 1993–95 58 (33–82) 17 (2–31) – – 2
Germany II 76 1992–96 55 (29–83) 26 (6–166) 23 8 13
Hungary 41 1980–94 52 (33–76) 42 (4–160) – 5 18
Iceland 70 1985–93 58 (29–95) 49 (2–92) – – 27
The Netherlandsa 11 1986–92 59 (39–73) 52 (7–103) – – 11
Norway 160 1984–94 60 (28–87) 55 (1–122) 23 8 48
Slovenia 17 1993–96 50 (37–68) 33 (24–48) 3 0 1
Spain 21 1994–96 55 (34–83) 11 (1–43) 4 1 3
Swedena 15 1987–92 51 (35–73) 55 (7–117) 1 2 15
UK I 19 1989–90 57 (36–79) 54 (21–70) – 2 6
UK II 44 1987–88 58 (30–85) 69 (8–123) 5 4 18
All cases 766 1978–96 57 (27–95) 57 (1–198) 97 42 231
– = information not available. a = selected cohort (all patients displayed cancer metastasis during the indicated follow-up time).
Table 2 Summary of clinical variables and LOH of APOC3 at 11q23 in the
studied European breast cancer cohort of 766 cases at time of diagnosis
Variable No. of cases No. of informative APOC3
cases (%) LOH %
Tumour size 703
< 2 cm 271 (39) 39
2–5 cm 353 (50) 41
> 5 cm 79 (11) 53
Positive node status 675
Yes 277 (41) 42
No 398 (59) 41
Distant metastasis 592
Yes 28 (5) 56
No 564 (95) 41
Oestrogen receptor status 548
Positive 355 (65) 45
Negative 193 (35) 38
Progesterone receptor status 541
Positive 315 (58) 44
Negative 226 (42) 42
Grade 397
I 52 (13) 43
II 196 (49) 39
III 149 (38) 51
Histology 727
Ductal 564 (78) 44
Lobular 111 (15) 39
Medullar 16 (2) 50
Tubular 16 (2) 38
Mucinous 5 (1) 60
Other 15 (2) 31LOH of APOC3 at 11q23 in breast cancer 881
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compared their observations. In the fluorescent-labelled
microsatellite analysis the data were analysed with appropriate
software (Pharmacia, Fragment Manager FM1.1; Perkin Elmer
Applied Biosystems, Gene Scan) by comparing normal and
tumour tissue allele peak sizes, heights and area ratios. In both
methods, intensity or signal ratio differences of at least 25%
(depending on the proportion of tumour cells or method used)
were considered sufficient for LOH assignment.
The Fisher’s two-tailed exact test, the Mann–Whitney test, the
Pearson test and the stepwise logistic regression analysis methods
were used for the statistical evaluation of associations between
LOH at 11q23 and clinical findings. Survival curves calculated by
Kaplan–Meier estimations were compared according to the log-
rank test. P-values below 0.01 were considered significant. Only
subpopulations with more than 40 breast cancer cases were
analysed independently.
RESULTS AND DISCUSSION
The results obtained from LOH analysis of the 11q23 subregion at
APOC3 are summarized in Tables 2 and 3. The APOC3 marker
was informative for determining LOH status in 78% of the studied
cases. LOH was observed in 42% of the tumours. The LOH
frequencies of the larger unselected subpopulations (with at least
40 patients) varied from 32% to 56%. In addition to the studied
cohort, differencies seen in the LOH incidences could also be due
to the analysis methods used. The LOH frequency was 47% in
the patients with recurrent/metastatic disease (data not shown).
Interestingly, primary tumours of the two small populations from
Sweden and The Netherlands that had been selected for the pres-
ence of a metastatic disease course displayed the highest LOH
frequencies (64% and 89% respectively).
According to the statistical analysis, no strong association was
found between primary tumour LOH at APOC3 and any of the
studied clinical variables (tumour size, node or metastasis status,
histoprognostic grade, histology type, oestrogen or progesterone
status, adjuvant therapy, bilaterality vs unilaterality, and family
history of cancer). Correlation was seen between occurrence of
LOH and disease onset at a higher age (P = 0.014). This could
reflect the observation that the frequency of LOH was 43%
(122/282) for the sporadic cases, but only 31% (22/70) for the
cases with a positive family history of cancer, known usually to
have earlier onset of the disease. No association was seen between
LOH and cancer-specific survival time (P = 0.146) or survival
after diagnosis of recurrence/metastasis (P = 0.987).
Although most of the studied cohorts represent cases from a
certain time period, they seemed to be clinically heterogeneous.
Nevertheless, we analysed separately all subpopulations consisting
of at least 40 patients. Only a slight correlation was observed
between LOH at APOC3 and a positive oestrogen status in the
Germany II cohort (P = 0.029), a greater tumour size and a more
advanced tumour grade in the France II cohort (P = 0.026 and
P= 0.024 respectively), and a more advanced tumour grade in the
sporadic cases of the Norwegian cohort (P = 0.025). We could not
detect a significant association between LOH for APOC3 and
cancer-specific survival times or survival after recurrence/metas-
tasis in any of the studied subpopulations. Only in the Finnish
cohort was a slight correlation between LOH and reduced survival
times after disease recurrence/metastasis seen (P = 0.026) (Figure
1). However, the clinical association was found to be much weaker
than in the initial analysis of the same cohort (P = 0.0004;
Winqvist et al, 1995). The difference could be explained by the
fact that in the current investigation, due to the longer follow-up
time, a greater number of patients showed relapse. In the previous
analysis, the follow-up time was approximately 3–5 years and,
altogether, 28 patients displayed a metastatic disease. In this study,
five more cases showed a metastatic disease course during the up-
dated follow-up time (mean > 6 years, range 5–117 months).
Interestingly, due to the prolonged follow-up time, the correlation
between LOH at 11q23 and shortened post-metastatic survival
time was not as strong as had been seen previously, suggesting that
in the Finnish cohort the adverse effect on survival is mainly
limited to the first 2–3 years after relapse.
The results presented here make it unlikely that the putative
survival factor gene on 11q23 would be situated very close to the
subregion containing the APOC3 gene. As our previous studies
have indicated that the crucial region of LOH seems to be located
between the D11S35 and APOC3 loci (Hampton et al, 1994;
Table 3 LOH at APOC3 (11q23) in different European populations
Country APOC3 LOH %
(cases with LOH/
informative cases)
Finland 41 (31/75)
France I 56 (20/36)
France II 41 (14/34)
France III 38 (12/32)
Germany I 37 (17/46)
Germany II 32 (18/57)
Hungay 52 (14/27)
Iceland 33 (20/60)
The Netherlandsa 89 (8/9)
Norway 45 (56/125)
Slovenia 29 (4/14)
Spain 58 (7/12)
Swedena 64 (9/14)
UK I 44 (8/18)
UK II 37 (14/38)
All cases 42 (252/597)
Sporadic cases 43 (122/282)
Familial cases 31 (22/70)
No information 44 (108/245)
aSelected cohort.
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Figure 1 Kaplan–Meier estimates for survival curves of breast cancer
patients after diagnosis of recurrence/metastasis in the Finnish cohort. The
patients with LOH at APOC3 in their tumours showed slightly reduced
survival times (P = 0.026, log-rank test)882 V Launonen et al
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Winqvist et al, 1995), it is possible that the survival factor gene
could be at a more proximal location. Interestingly, one additional
subregion exhibiting LOH on chromosome 11q23 has been
mapped closer to the DDX10 and ATM genes (Laake et al, 1997;
Hui et al, 1996). The involovement of this subregion was
confirmed by our parallel study on LOH of 11q23. Possible addi-
tional targets of LOH on chromosome 11q could include the
CHEK1 and LOH11CR2A genes (Furnari et al, 1997; Sanchez et
al, 1997; Monaco et al, 1997). However, LOH11CR2A gene muta-
tions have not so far been detected in breast, ovarian or lung
tumours (Monaco et al, 1997). As chromosome 11q seems to
harbour multiple genes important for tumour development, it is
likely that the size and number of deleted chromosomal segments
could be important for determining their clinical effects.
In conclusion, LOH of 11q23 at APOC3 is a frequent finding in
primary breast tumours, and it is even more common in the
tumours of patients developing a more advanced disease.
However, LOH was not seen to be strongly associated with any of
the studied clinical variables, suggesting that the putative survival
factor gene on 11q23 is not located in the immediate vicinity of the
APOC3 locus, but more likely further proximal towards the chro-
mosomal subregion harbouring the DDX10 and ATM genes.
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